Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia
Status:
Terminated
Trial end date:
2019-08-22
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if rigosertib can help to control MF in
patients with anemia. The safety of this drug will also be studied.
This is an investigational study. Rigosertib is not FDA-approved or commercially available.
It is currently being used for research purposes only. The study doctor can explain how the
study drug is designed to work.
Up to 35 participants will be enrolled in this study. All will be enrolled at MD Anderson.